You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Merck
Baxter
Moodys
Express Scripts

Last Updated: August 10, 2020

DrugPatentWatch Database Preview

PERSANTINE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Persantine patents expire, and when can generic versions of Persantine launch?

Persantine is a drug marketed by Boehringer Ingelheim and is included in one NDA.

The generic ingredient in PERSANTINE is dipyridamole. There are eighteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the dipyridamole profile page.

US ANDA Litigation and Generic Entry Outlook for Persantine

A generic version of PERSANTINE was approved as dipyridamole by BARR on October 3rd, 1990.

  Start Trial

Drug patent expirations by year for PERSANTINE
Recent Clinical Trials for PERSANTINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Henan University of Traditional Chinese MedicinePhase 1/Phase 2
Affiliated Hospital of Yunnan University of Traditional Chinese MedicinePhase 1/Phase 2
Peking University First HospitalPhase 1/Phase 2

See all PERSANTINE clinical trials

Pharmacology for PERSANTINE

US Patents and Regulatory Information for PERSANTINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim PERSANTINE dipyridamole TABLET;ORAL 012836-003 Dec 22, 1986 AB RX Yes No   Start Trial   Start Trial   Start Trial
Boehringer Ingelheim PERSANTINE dipyridamole TABLET;ORAL 012836-004 Feb 6, 1987 AB RX Yes No   Start Trial   Start Trial   Start Trial
Boehringer Ingelheim PERSANTINE dipyridamole TABLET;ORAL 012836-005 Feb 6, 1987 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Baxter
Merck
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.